Drug intelligence / Profile preview

Mecloxamine

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Mecloxamine is a small molecule anticholinergic agent with sedative and hypnotic properties. It has been primarily used in combination with other medications—such as caffeine, ergotamine, and acetaminophen—for the treatment of headaches and migraines. Its mechanism of action involves antagonism at muscarinic acetylcholine receptors, leading to its anticholinergic effects[1][2][4]. Mecloxamine is classified chemically as a diarylmethane compound[3].

Other names: mecloxaminemecloxaminaMecloxamine [INN]U8V8239CRMU-8V8239CRMU 8V8239CRM

Targets

mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on Mecloxamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mecloxamine.

Explore the full profile